IFF Stock Analysis: International Flavors | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 22.369m USD | 12M Return: 34.4% | US4595061015 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 208M
EPS Trend: 59.0%
Qual. Beats: 0
Rev. Trend: -79.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
International Flavors & Fragrances Inc. (NYSE: IFF) is a New York-headquartered specialty ingredients company that manufactures and markets food, beverage, health and biosciences, scent, and related products globally, operating through four reportable segments: Taste, Food Ingredients, Health & Biosciences, and Scent. The Taste segment supplies flavor systems for savory products, beverages, sweets, and dairy, while Food Ingredients provides natural and plant-based specialty ingredients, antioxidants, anti-microbials, savory solutions, inclusion products, and protein-based formulations. The Health & Biosciences segment produces enzymes, food cultures, probiotics, and specialty ingredients for food, animal nutrition, grain processing, and home/personal care applications, and the Scent segment develops fragrance compounds and ingredients. The company was incorporated in 1909 and is classified within the Materials sector under the Specialty Chemicals sub-industry.
IFF operates a business-to-business model, selling proprietary ingredient formulations and fragrance compounds to consumer goods manufacturers rather than directly to end consumers, which is typical of the flavors and fragrances industry. The sector is highly consolidated, with a small number of global players supplying the majority of taste, scent, and functional ingredient needs to food, beverage, personal care, and pharmaceutical customers worldwide.
- Fragrance and scent segment margins expand on premium innovation
- Health & Biosciences enzymes drive growth in animal nutrition and grain processing
- Debt reduction and integration of DuPont N&B assets improves capital allocation
| Net Income: 195.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.72 > 1.0 |
| NWC/Revenue: 46.79% < 20% (prev 16.01%; Δ 30.78% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.14b > Net Income 195.0m |
| Net Debt (7.07b) to EBITDA (1.20b): 5.90 < 3 |
| Current Ratio: 1.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (253.0m) vs 12m ago -1.56% < -2% |
| Gross Margin: 38.87% > 18% (prev 36.38%; Δ 2.49% > 0.5%) |
| Asset Turnover: 36.47% > 50% (prev 42.97%; Δ -6.50% > 0%) |
| Interest Coverage Ratio: 1.87 > 6 (EBIT TTM 346.0m / Interest Expense TTM 185.0m) |
| A: 0.17 (Total Current Assets 9.28b - Total Current Liabilities 4.96b) / Total Assets 24.8b |
| B: -0.14 (Retained Earnings -3.56b / Total Assets 24.8b) |
| C: 0.01 (EBIT TTM 346.0m / Avg Total Assets 25.3b) |
| D: 1.15 (Book Value of Equity 13.3b / Total Liabilities 11.5b) |
| Altman-Z'' = 1.97 = BBB |
| DSRI: 1.14 (Receivables 1.90b/2.00b, Revenue 9.23b/11.1b) |
| GMI: 0.94 (GM 36.38% / 38.87%) |
| AQI: 0.83 (AQ_t 0.50 / AQ_t-1 0.60) |
| SGI: 0.83 (Revenue 9.23b / 11.1b) |
| TATA: -0.04 (NI 195.0m - CFO 1.14b) / TA 24.8b) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of November 08, 2026, the stock is trading at USD 82.62 with a total of 2,893,568 shares traded. Over the past week, the price has changed by -11.18%, over one month by -1.55%, over three months by -1.82% and over the past year by +34.38%.
Current recommended Stop Loss: 79.50 (which is 3.8% or 1.2 ATR below the current price).
International Flavors has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy IFF.
- StrongBuy: 10
- Buy: 4
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 97.5 | 18% |
P/E Trailing = 250.4857
P/E Forward = 22.779
P/S = 2.0749
P/B = 1.6829
P/EG = 2.276
Revenue TTM = 9.23b USD
EBIT TTM = 346.0m USD
EBITDA TTM = 1.20b USD
Long Term Debt = 4.74b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.62b USD (from shortTermDebt, last quarter)
Debt = 7.34b USD (from shortLongTermDebtTotal, last quarter) + Leases 544.0m
Net Debt = 7.07b USD (calculated: Debt 7.34b - CCE 272.0m)
Enterprise Value = 29.4b USD (22.4b + Debt 7.34b - CCE 272.0m)
Interest Coverage Ratio = 1.87 (Ebit TTM 346.0m / Interest Expense TTM 185.0m)
EV/FCF = 58.99x (Enterprise Value 29.4b / FCF TTM 499.0m)
FCF Yield = 1.70% (FCF TTM 499.0m / Enterprise Value 29.4b)
FCF Margin = 5.41% (FCF TTM 499.0m / Revenue TTM 9.23b)
Net Margin = 2.11% (Net Income TTM 195.0m / Revenue TTM 9.23b)
Gross Margin = 38.87% ((Revenue TTM 9.23b - Cost of Revenue TTM 5.64b) / Revenue TTM)
Gross Margin QoQ = 42.48% (prev 43.65%)
Tobins Q-Ratio = 1.19 (Enterprise Value 29.4b / Total Assets 24.8b)
Interest Expense / Debt = 2.52% (Interest Expense 185.0m / Debt 7.34b)
Taxrate = 33.54% (54.0m / 161.0m)
NOPAT = 230.0m (EBIT 346.0m * (1 - 33.54%))
Current Ratio = 1.87 (Total Current Assets 9.28b / Total Current Liabilities 4.96b)
Debt / Equity = 0.55 (Debt 7.34b / totalStockholderEquity, last quarter 13.3b)
Debt / EBITDA = 5.90 (Net Debt 7.07b / EBITDA 1.20b)
Debt / FCF = 14.16 (Net Debt 7.07b / FCF TTM 499.0m)
Total Stockholder Equity = 13.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.77% (Net Income 195.0m / Total Assets 24.8b)
RoE = 1.41% (Net Income TTM 195.0m / Total Stockholder Equity 13.9b)
RoCE = 1.86% (EBIT 346.0m / Capital Employed (Equity 13.9b + L.T.Debt 4.74b))
RoIC = 1.08% (NOPAT 230.0m / Invested Capital 21.2b)
WACC = 6.46% (E(22.4b)/V(29.7b) * Re(8.03%) + D(7.34b)/V(29.7b) * Rd(2.52%) * (1-Tc(0.34)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -27.85 | Cagr: -0.52%
[DCF] Terminal Value 77.97% ; FCFF base≈432.2m ; Y1≈495.4m ; Y5≈729.2m
[DCF] Fair Price = 15.31 (EV 11.0b - Net Debt 7.07b = Equity 3.91b / Shares 255.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 59.05 | EPS CAGR: 5.13% | SUE: 0.10 | # QB: 0
Revenue Correlation: -79.68 | Revenue CAGR: -5.77% | SUE: 0.12 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.94 | Chg30d=-8.40% | Revisions=-29% | Analysts=4
EPS current Year (2026-12-31): EPS=3.15 | Chg30d=-2.87% | Revisions=+57% | GrowthEPS=-25.0% | GrowthRev=-30.9%
EPS next Year (2027-12-31): EPS=3.93 | Chg30d=-0.88% | Revisions=-38% | GrowthEPS=+24.6% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -6% (up=6, down=7)